Compare uniQure N.V. Ordinary Shares (QURE) vs State Street Corporation Common Stock (STT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs State Street Corporation Common Stock — how do they compare? uniQure N.V. Ordinary Shares trades at $20.71 (market cap $1.45B), while State Street Corporation Common Stock trades at $168.25 (market cap $45.84B). The key difference: State Street Corporation Common Stock is far larger — about 31.6× uniQure N.V. Ordinary Shares's market cap, and State Street Corporation Common Stock pays a 2.21% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and State Street Corporation Common Stock for 2 Days on average.
| QURE | STT | |
|---|---|---|
Market Cap | $1.45B | $45.84B |
Volume | 3,323,243 | 5,895,682 |
Sector | Health | Financials |
52-Week High | $70.59 | $194.26 |
52-Week Low | $9.03 | $111.37 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $707.46M | $67.08B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
State Street (STT) trades at $173.99, down 0.54% with bearish technical signals despite strong Q3 2026 earnings beat. The stock faces headwinds from a revenue miss and ongoing investigation, though fundamentals show robust profitability with 22.95% net margin and consistent earnings growth. Analyst consensus remains positive with $183.55 price target, but technical indicators show selling pressure with support at $172.
Outlook is mixed with strong fundamentals supporting long-term value, but near-term risks from the securities investigation and bearish technicals create uncertainty. The 13% revenue growth and record AUM provide upside potential, though investors should monitor legal developments and expense trends that could impact sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About State Street Corporation Common Stock
State Street provides investment servicing, custody, and asset management services to institutional investors. Its asset management business includes the SPDR ETF range.
Read more on STT →
